News & Events

Partnership combines Sirona Dx‘s technology-agnostic spatial biology expertise with Parhelia‘s Spatial Station platform to improve reproducibility, increase throughput, and reduce costs across spatial biology workflows. ASHLAND, Ore. and PORTLAND, Ore., July 21, 2026 /PRNewswire/ — Parhelia Biosciences and Sirona Dx today announced a strategic partnership aimed at advancing the adoption of spatial biology in translational research, clinical trials, and precision health initiatives. While spatial biology technologies have transformed researchers’ ability to understand tissue architecture and cellular interactions, many workflows remain highly manual, costly, and difficult to scale. These challenges often limit reproducibility across laboratories and create barriers to broader clinical deployment. Through this partnership, Sirona Dx and Parhelia will combine complementary expertise to address these limitations. Sirona Dx brings extensive experience across a wide range of spatial biology technologies, enabling researchers to select and optimize the right platform and assay for each application. Parhelia contributes the Spatial Station, a configurable automation platform designed to standardize complex spatial biology workflows, reduce hands-on effort, and improve consistency across studies and sites. “Spatial biology has reached an inflection point where the next challenge is no longer simply generating data, it’s generating high-quality, reproducible data at scale,” said Nikolay Samusik, Chief Executive Officer of Parhelia Biosciences. “By […]

New integrated offering enables pharma sponsors to capture and translate the full value of spatial proteomics data from tissue to insight in a single engagement. TEL AVIV, Israel–(BUSINESS WIRE)–Nucleai, a leader in AI-powered spatial biology analytics, and Sirona Dx, a Technical CRO, specialized in spatial biology and single-cell services, today announced a strategic partnership to deliver a fully integrated and scalable spatial proteomics solution for pharmaceutical and biotechnology companies. Spatial proteomics platforms are generating increasingly rich and complex tissue data, yet a significant portion of that data’s biological value remains unrealized. Critical insights, including novel spatial biomarkers, treatment response signatures, and patient stratification patterns, are often under extracted due to sub-optimal assay development and fragmentation across assay development, imaging, and analytics. As multiplex imaging technologies advance, the gap between data generation and actionable insight continues to widen, leaving substantial value unrealized. This partnership introduces a premium, fully integrated offering for pharma sponsors, delivered as a single engagement unified across the entire workflow. Sirona Dx leads assay design, development, and validation to ensure high-quality image generation, while Nucleai delivers AI-powered spatial analytics from feature extraction through biomarker discovery and biological interpretation. Together, the companies provide a seamless end-to-end solution in which […]

BRIDGEWATER, N.J., April 11, 2025 /PRNewswire/ — Hamamatsu Photonics, a global leader in whole slide imaging and spatial proteomics solutions, is pleased to announce a strategic partnership with Sirona Dx (SDX) as its Technology Access Partner. This collaboration will streamline the technology evaluation process by providing customers with access to deep spatial biology expertise within a GCLP / CLIA accredited laboratory for imaging, staining, and bioinformatics analysis, removing barriers to adoption. Enhancing Technology Evaluation in Spatial Proteomics As the demand for spatial proteomics solutions grows, researchers and laboratories often face challenges in evaluating new technologies due to the complexities of sample preparation, staining, and imaging. To simplify this process, Hamamatsu has established the Technology Access Program (TAP), ensuring that potential users can assess MoxiePlex Systems without the need to handle staining workflows, panel development, and bioinformatics analysis. SDX brings deep expertise in spatial omics and technology validation, bridging a critical knowledge gap for effective customer evaluations. Through this partnership, Hamamatsu and SDX will provide: Seamless technology access – Potential customers can now evaluate Hamamatsu’s spatial proteomics technology in a regulatory compliant laboratory without concerns about sample preparation, imaging workflows, and data analysis. Flexibility and scalability – Supporting a diverse range of needs […]

At Sirona Dx, we’re proud to have been at the forefront of this revolutionary field for over six years. In collaboration with leading platform innovators like Standard BioTools, Akoya, Lunaphore, Nanostring, and most recently, Hamamatsu, we’ve continually pushed the boundaries of spatial biology. From platform selection to assay development and advanced analysis, our dedicated team remains steadfast in delivering cutting-edge solutions and services for our clients. Here’s to a future of innovation and discovery! 💡 Read the full article here: https://lnkd.in/epNmXHh9

PredxBio, Inc., a leader in spatially intelligent biology, and Sirona Dx, a leader in single cell multi-omics, analytical services, have announced a strategic partnership aimed at reshaping the landscape of drug discovery and development. This collaboration marks a pivotal moment in the industry, leveraging Explainable AI-Driven Spatial Biology with a groundbreaking new platform SpaceIQ™ to unlock the potential of genomic, proteomic, and transcriptomic data through advanced spatial analytics. PITTSBURGH and PORTLAND, Ore., April 2, 2024 /PRNewswire-PRWeb/ — PredxBio, Inc., a leader in spatially intelligent biology, and Sirona Dx, a leader in single cell multi-omics, analytical services, have announced a strategic partnership aimed at reshaping the landscape of drug discovery and development. This collaboration marks a pivotal moment in the industry, leveraging Explainable AI-Driven Spatial Biology with a groundbreaking new platform SpaceIQ™ to unlock the potential of genomic, proteomic, and transcriptomic data through advanced spatial analytics. The partnership combines PredxBio’s game changing spatial analytics platform, SpaceIQ™, with Sirona Dx’s unparalleled expertise in multiplex assay development. Together, they will identify novel spatial signatures in high-plex assays, predicting responses to therapy and informing treatment decisions. Sirona Dx will serve as a Contract Research Organization (CRO) partner, facilitating the deployment of Explainable AI-based diagnostic […]

Pioneers of technology agnostic, spatial biology services since 2018. Our experienced team is here to help. Contact us for a free consultation to figure out the best approach for your spatial biology study.   NanoString is honored to partner with Macrogen Inc., Propath UK, and Sirona Dx to accelerate access to spatial biology capabilities for biopharma companies around the world. These specialty CROs provide biomarker testing services for drug developers and academic research institutions. https://lnkd.in/g7uzATGF #spatialbiology #BioPharma  

Join us at the AACR 2023 Annual Meeting at booth #3442 to learn about our unique spatial-omics service capabilities that span the latest technology platforms. Discuss the best single cell multi-omics approaches for deep immunophenotyping and characterization of the tumor microenvironment to drive biomarker discovery and uncover new opportunities for therapeutic intervention. We look forward to updating you with our latest service capabilities and hear about the latest advances in oncology research from the world’s experts.

LAUSANNE, Switzerland and PORTLAND, OR, USA– February 23, 2023 – 5:00 pm (CET) | 8 am (PST) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Sirona Dx, a leader in multi-omics, single-cell analytical services, today announced a strategic collaboration in which Sirona Dx will become the first US-based Contract Research Organization (CRO) to offer Lunaphore’s flagship COMET™ spatial biology platform as a service. COMET™ will complement Sirona Dx’s portfolio of research service offerings to meet the needs of researchers and biopharma teams across various disciplines. Lunaphore’s COMET™ platform is the only fully automated, high-throughput, hyperplex platform with superior tissue profiling capabilities. Its capacity allows the generation of high-quality and reproducible data on large cohorts of samples in days. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, enabling customers to use their trusted antibodies and making panel design fast and flexible. Thanks to its versatility, COMET™ has a wide range of research applications across multiple disciplines and all stages of research and drug development. Sirona Dx is a highly-specialized technical CRO and pioneer of single-cell and spatial biology, having launched ultra-high parameter, multiplexed single-cell services to biopharma in 2018. Their innovative, technology-agnostic […]

Scailyte, a single-cell biomarker discovery company and Sirona Dx, a leader in multiomic single-cell analytical services, announce a strategic partnership to accelerate the development of Advanced Therapies. The companies will create a powerful biomarker discovery engine, leveraging Sirona Dx technical and laboratory workflow solutions in combination with Scailyte’s AI-driven data analytics platform ScaiVision™ to serve Biopharma and Biotech. The joint platform will enable discovery and validation of ultra-sensitive biomarkers thanks to Sirona Dx leading technical capabilities in single-cell analysis, and the ability of ScaiVision™ to detect complex molecular signatures in biological samples. The combined workflow will focus on applications within oncology and immunology, including qualification and stratification of patients for clinical trials, analysis of clinical trial results on a deep cellular level or and to advance efficacy and manufacturing processes during CGT development. The first wave of projects with pharmaceutical and diagnostic companies, will begin in Q2-2022. “We are truly excited to partner with Sirona Dx. Precision medicine in Immuno-Oncology is still a challenge today, which requires full mastery and exploitation of the most advanced multi-omics approaches, including single-cell technologies and analytics. With our combined expertise in single-cell technologies applied to translational science, AI and biomarker discovery, we will provide […]

Ultivue Announces Co-Marketing Agreement with Sirona DX for Multiplexed Tissue Biomarker Solutions for Precision Medicine CAMBRIDGE, Mass. & PORTLAND, Ore.–(BUSINESS WIRE)–Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, and Sirona Dx, a technical contract research organization (CRO), providing advanced, single cell proteomics and genomics services to accelerate the pace of immunotherapy and targeted therapy development, announced a co-marketing agreement to deliver tissue-based spatial multiplexed immunophenotyping solutions for translational research groups and biopharma. Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique solutions for use in both multiplex immunofluorescence (mIF) imaging and spatial phenomics. Its proprietary InSituPlex® technology, designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in precious tissue samples combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology. “Our InSituPlex technology offers valuable profiling of the tissue and expands the depth of information possible from a single section that is complementary to the high-parameter capabilities offered by Sirona Dx. We believe this joint offering will now provide researchers a seamless workflow enabling a far more efficient biomarker discovery […]